"mRNA" vaccines and inflammation of the myocardium/pericardium

Article Sidebar

pdf (Italiano)
Published: Dec 30, 2021
DOI: https://doi.org/10.30459/2021-16
Keywords:
SARS-COVID-2, vaccini a “mRNA”, terapie mediche, vantaggi delle vaccinazioni, long Covid, cuore, infiammazione, vaccino SARS-COVID-2, , advantages of vaccinations, medical therapies, long Covid

Main Article Content

Claudio Di Veroli
Dirigente Responsabile del ‘Servizio dell’Ipertensione Arteriosa e delle Malattie Metaboliche e Renali’ “POLO ROMANO DELL’IPERTENSIONE ARTERIOSA” presso la Casa di Cura “San Domenico

Abstract

After a short introduction, the relationship between mRNA vaccination with le rebrand myocardial and pericardial inflammation was highlighted.


The most important data and considerations, chosen from the   medical literature and from the main research institutes, are reported. These inflammations are resolved without results or after a few days with “essential medical care".


Deaths are few and almost all these subjects suffer serious diseases.


The conclusions underline that the benefits of vaccinations, despite the rare inflammation mainly in younger people, reduce the risk of  an unfavorable clinical evolution.

Downloads

Download data is not yet available.

Article Details

How to Cite
[1]
Di Veroli, C. 2021. "mRNA" vaccines and inflammation of the myocardium/pericardium. Italian Journal of Prevention, Diagnostic and Therapeutic Medicine. 4, 3 (Dec. 2021), 8-12. DOI:https://doi.org/10.30459/2021-16.
Issue
Vol. 4 No. 3 (2021): IJPDTM
Section
Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

AGENZIA DIRE: www.dire.it.

AIFA: “Rapporto sulla Sorveglianza dei vaccini COVID-19”.

AIFA: www.aifa.gov.it.

Bozkurt DB, Kamat I, Hotez PJ (per il CDC “Center for Disease Control and prevention” degli USA): “Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults”. Circulation 2021; 144: 471-484.

Golpour A, Patriki D, Hanson PJ et al: “Epidemiological Impact of Myocarditis”. Journal Clin Med 2021; 10 (4): 603. DOI: 10.3390/jcm10040603.

Hause AM, Gee J, Baggs J, Abara WE et al (per il CDC “Center for Disease Control and prevention” degli USA): “Covid-19 vaccine

safety in adolescents aged 12-17 years”. United State 2021; 70 (31): 1053-1058. DOI: http://dx.doi.org/10.15585/mmwr.mm7031e1.

Kim HW, Jenista ER, Wendell DC, Azevedo CF et al: “Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination”.

JAMA-Cardiology 2021; 6 (10): 1196-1201. DOI: 10.1001/jamacardio.2021.2828.

Marshall M, Ferguson ID, Lewis P, Jaggi P et al: “Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech

COVID- 19 Vaccination”. Pediatrics 2021; 148 (3). DOI: 10.1542/peds.2021-052478.

Montgomery J, Ryan M, Engler R, Hoffman D et al: “Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military”. JAMA-Cardiology 2021; 6 (10): 1115-1117 (Pubblicato on-line). DOI: 10.1001/jamacardio.2021.2833.

1Rosner CM, Genovese L, Tehrani BM, Atkins M et al: “Myocarditis Temporally Associated with COVID-19 Vaccination”. Circulation 2021; 144: 502-505. DOI.org/10.1161/CIRCULATIONAHA.121.055891.

Sagar S, Liu PP, Cooper LT et al: “Myocarditis”. Lancet 2012; 379 (9817): 738–747.DOI: 10.1016/S0140-6736(11)60648-X.